Key Highlights

  • Clover Health shares are up 14.01% in pre-market trading.
  • Q2 2026 revenue reached $743.2 million, beating the $728.3 million estimate.
  • Adjusted EPS of $0.05 beat estimates of $0.04, a 29.40% beat.
  • Medicare Advantage membership grew 48% year over year to 157,000 average members.
  • The company raised full-year 2026 revenue guidance to $2.92 billion to $3.00 billion.

Shares Surge on Strong Beat and Membership Growth

Clover Health (NASDAQ:CLOV) is trading sharply higher today after the health insurance technology company reported second-quarter results that beat estimates on both revenue and earnings. Shares rose as much as 14.01% to $4.72 in pre-market trading, extending Wednesday's after-hours surge, after the company posted stronger-than-expected second-quarter results following the closing bell.

Clover Health Investments, headquartered in Franklin, Tennessee and founded in 2014, is a physician enablement company focused on providing Medicare Advantage plans to seniors who have historically lacked access to affordable, high-quality healthcare. The company reported second-quarter revenue of $743.2 million, above the $728.3 million estimate, with adjusted EPS of $0.05 beating the $0.04 consensus estimate.

Guidance Raised as Membership Accelerates

Medicare Advantage membership grew 48% year over year to 157,000 average members, total revenue reached $743.2 million, up 54% year over year, adjusted EBITDA totaled $41 million, and GAAP net income was $28 million, while first-half 2026 GAAP profitability totaled $67 million with total revenue of $1.5 billion.

Following a court order and CMS recalculation, all of Clover's Medicare Advantage members are now enrolled in 4.5-star rated plans for payment year 2027, though CMS has filed notice of intent to appeal the district court's decision, which management believes the higher rating provides flexibility but does not itself dictate the model's economics, which are driven by Clover Assistant.

Cohort Economics Improving

Cohort economics are improving as expected, with members typically improving by about $70 PMPM in gross profit from year one to year two, and the 2025 cohort is expected to be roughly 21% of membership by year three. With Clover Assistant coverage now extended into the new New Jersey and Georgia cohorts, in the low 60% range versus two-thirds of the company for the second half of 2026, the company expects gross profit to be stronger in Q3 than in Q4 due to seasonality, with adjusted EBITDA remaining positive in Q3 before a typical seasonal loss in Q4. Management expressed increasing confidence in 2027 as the company matures into a larger, more established membership base, with continued cohort maturation and additional operating leverage, though formal 2027 guidance has not yet been provided pending final bid economics and enrollment figures.

The company raised full-year 2026 guidance to revenue of $2.92 billion to $3.00 billion, adjusted EBITDA of $70 million to $85 million, and GAAP net income of $20 million to $35 million.

Conclusion

Clover Health's strong second-quarter results and raised guidance reflect accelerating Medicare Advantage membership growth alongside continued profitability improvements. With a favorable star rating outcome and improving cohort economics, the company appears positioned for continued growth into 2027, though the pending CMS appeal remains a factor to watch.

This article is for informational purposes only and does not constitute financial, investment, or trading advice. Readers should conduct their own research or consult a licensed financial advisor before making any investment decisions.